Accelerating the Future of Dermatology Therapeutics Through a Drug Development Lens
The Dermatology Drug Development Summit is the definitive industry-led forum uniting a driven community trailblazing innovative drug discovery research and clinical strategy to collectively improve the long-term quality of life for patients with immuno-inflammatory disease.
Recognizing how disease heterogeneity and biomarker discovery is triggering a new wave of novel drug discovery efforts while clinical pipelines see increasing competition, staying ahead of the curve to develop differentiated candidates for novel inflammatory candidates had never been more important.
Who Did You Meet?
The 9th Dermatology Drug Development meeting united 120+ key voices in pharma, biotech, investment, across discovery biology, preclinical R&D, early development, clin dev, med affairs, and pipeline advancement.
From C-Level executives to senior scientists, came together in November 2025 to hear the latest unpublished data, hear heated panel discussion, structured group discussions and deep-dive workshops you won’t find anywhere else.
What Your Peers Have to Say
2025 Speaker Testimonials:
“The Dermatology Drug Development Summit provides an opportunity to engage in in-depth, scientifically grounded discussions on the evolving treatment landscape for inflammatory skin diseases. The program facilitates meaningful exchange on emerging mechanisms, therapeutic innovation, and clinical translation, with focused sessions addressing key development challenges in areas such as immune modulation, barrier dysfunction, and chronic inflammation.
With contributions from leading experts across academia, biotech, and pharma, the meeting offers direct insight into current thinking and future directions in the development of therapies for inflammatory skin diseases. For those involved in advancing treatments in this space, the clarity, relevance, and scientific rigor of the discussions make this summit uniquely valuable.”
Shawn Seong, Chief Executive Officer, Shaperon Inc
2024 Attendees:
“The high quality and accessibility of the participants, both speakers and attendees, and the networking opportunities. The breaks were long enough to meet other participants and have productive conversations. The size of the conference was just right - small enough to be intimate and not overwhelming but large enough to meet many people.”
Michael Jacobson, CEO & CSO, Alnivo Therpauetics